higher than self. Using DBDC questions seems to have additional benefit of refining open ended questions. These results were higher especially in parametric estimation models using only DBDC questions. This observation cautions us of selecting a specific analytic method may influence the results. CONCLUSIONS: This study is the first step toward resolution of controversies around economic evaluations of healthcare in Korea and hopes to encourage more local research on this issue.
PHP71 IMPACT OF THE MEDICARE PART D COVERAGE GAP ON PRESCRIPTION DRUG UTILIZATION AND MEDICATION ADHERENCE
Naik R 1 , Borrego M 2 , Dodd M 2 , Raisch D 2 , Khan N 3 , Bakhireva L 2 , Gupchup G 4 , Cunico L 2 1 Allergan, Inc., Irvine, CA, USA, 2 University of New Mexico, Albuquerque, NM, USA, 3 Oxford Outcomes Ltd., Morristown, NJ, USA, 4 Southern Illinois University Edwardsville, Edwardsville, IL, USA OBJECTIVES: To assess impact of the Medicare Part D coverage gap on prescription drug utilization and medication adherence using data from Medicare beneficiaries enrolled in a large health plan in New Mexico in 2007. METHODS: Quasi-experimental, retrospective, pre-post with control group study design was utilized. Preand post-coverage gap prescription drug utilization and medication adherence of beneficiaries enrolled in a health plan with no prescription drug coverage during the coverage gap (no coverage plan) was compared with generic drug coverage (generic coverage plan) and full prescription drug coverage (full coverage plan) plan beneficiaries. Prescription drug utilization was assessed using total number of prescriptions per member. Medication adherence was measured using Medication Possession Ratio and the Proportion of Days Covered (PDC). Difference-in difference analysis (DiD) was used to compare pre-and post-coverage gap prescription drug utilization and medication adherence between the three plans. RESULTS: Of the 14,846 beneficiaries who met inclusion and exclusion criteria, 2,661 (17.92%) entered the coverage gap in 2007. DiD analyses indicated that beneficiaries in the no coverage plan filled significantly fewer prescriptions in the post-coverage gap period, than beneficiaries in the full (14.67 fewer prescriptions; pϭ0.001) and generic (12.52 fewer prescriptions; pϭ0.001) coverage plans. Significant decrease in post-coverage gap medication adherence was observed between no coverage and full coverage plan beneficiaries with respect to statins (5.8%), ARBs (16%) and PPIs (18.1%). Significant decrease in post-coverage gap medication adherence was observed between no coverage and generic coverage plan beneficiaries utilizing statins (1.1%) and ARB's (12%). No significant differences were observed between full and generic coverage plan beneficiaries. Significant differences in adherence were found only when adherence was measured using the PDC. CONCLUSIONS: Lack of prescription drug coverage during the Medicare Part D coverage gap may lead to decreased utilization and adherence to certain classes of prescription drugs.
PHP72 ASSESSING THE QUALITY OF PHARMACOECONOMIC STUDIES IN INDIA: A SYSTEMATIC REVIEW
Desai P 1 , Chandwani H 1 , Rascati K 2 1 University of Texas at Austin, Austin, TX, USA, 2 University of Texas, College of Pharmacy, Austin, TX, USA OBJECTIVES: The aim of the study was to evaluate the quality of pharmacoeconomic studies based in India. METHODS: A literature search was conducted using PubMed, Medline, EconLit, PsycInfo and Google Scholar to identify published work on pharmacoeconomics studies based in India. Original research studies that evaluated pharmaceuticals, and were conducted between 1990 and 2010 in India were included. Two reviewers independently reviewed the articles using a subjective 10-point scale (10 being the highest) and the 100-point 'Quality of Health Economic Studies' (QHES) questionnaire (100 being the highest). RESULTS: The included articles (nϭ29) were published in 23 different journals. Only 9 articles were published in journals based in India. The first article was published in 1998. Each article was written by an average of five authors. The majority of authors resided in India (62%) at the time of publication and had a medical background (90%). Cost-effectiveness analysis was the most frequently used method of analysis (79%). The source of funding and study perspective was not listed in 45% and 41% of the studies respectively. The study design was a randomized controlled trial for 41% of the studies. The mean subjective quality score of all the articles (n ϭ 29) was 7.8 (SDϭ1.3) and the mean QHES scores for the studies evaluating costs and outcomes (n ϭ 24) was 86 (SDϭ6). The quality score was significantly (pՅ0.05) related to country of residence of primary author (non-Indiaϭhigher) and the study design (randomized controlled trialsϭhigher). CONCLUSIONS: The need for economic evaluation of pharmaceuticals is imperative, especially in developing countries like India; because it can help decision makers allocate scarce resources in a justifiable manner. Standardization of guidelines, and improved pharmacoeconomic education -starting from the undergraduate level to specialization -are two suggestions to help to improve the quality of the pharmacoeconomic research in India. . Logical combinations of keywords related to effectiveness, generalisability, external validity, transferability, Europe and review were searched. RESULTS: A total of 326 articles were initially identified and ten formed the bases of the review. Nine were reviews or original cost-effectiveness studies and relevant data on the effectiveness results was extracted. First, we found that there is a common assumption in the literature that relative efficacy is constant across countries and therefore generalisable. Less is known about whether relative effectiveness is indeed similar or different. Second, we grouped the factors that could potentially introduce variation in relative effectiveness: (i) patients and disease characteristics; (ii) comparators used; (iii) different measures of health outcomes; (iv) variations in clinical practice. Third, no observational studies were identified. Evidence from studies using efficacy data, mainly from RCTs, was mixed; three studies found no differences in clinical outcomes across countries, one study found differences due to patients' characteristics and severity and another study using multilevel analysis found country and patients characteristics explaining partly the heterogeneity of treatment effects. One review report differences in clinical practice as one major causes of variations in clinical outcomes between countries. CONCLUSIONS: The literature was scarce and therefore more evidence is needed before any statement can be claimed on the existence of variations in relative effectiveness or efficacy in different countries. Future collaboration among the MS harmonising methodology, generating data and sharing patients' registry data will be crucial to produce this evidence. OBJECTIVES: Evidence has recently emerged regarding the presence of investigator learning curves in the context of clinical trials (i.e., the association between clinical protocol departures and patient enrollment sequence). We reviewed the literature to identify factors contributing to clinical trial learning curves and potential impacts of learning curves on outcomes accuracy, patient safety and overall trial success. METHODS: The PubMed database was searched for studies describing clinical trial learning curve effects and potential solutions to these effects, using search term combinations including "clinical trial", "clinical protocol", "learning curve", and "enrollment sequence". RESULTS: Learning curve effects were identified in trials including those for treatment of sepsis (PROWESS and ADDRESS) and high-risk cardiac disease (VALIANT). Outcomes of these trials potentially resulting from learning curves included ambiguous treatment benefit, increased adverse events and mortality, and overall trial failure. Potential contributing factors include those related to study site (e.g., large multicenter trials; sites with poor enrollment or previous trial experience; inexperienced staff and high staff turnover), study protocols (e.g., imprecise or complex protocols), and disease severity. Preventing such learning curve effects would likely have required extensive trial site and staff screening and training, as well as improved trial protocol design prior to first patient enrollment. Clinical trial simulation, a methodology identified in several reports, could potentially address clinical trial learning curves by improving protocol design and staff competence. This approach, which focuses on human factors involved in conducting clinical protocols, offers the potential to improve the accuracy of measured trial outcomes and decrease the likelihood of premature trial A24 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4
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